{
  "title": "Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease",
  "itunes:title": "Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease",
  "pubDate": "Thu, 01 Jul 2021 16:00:00 +0000",
  "guid": "a35f3dc5-6997-49ff-a90e-23e8aec86a83",
  "link": "https://psychopharmacology.libsyn.com/psychotropics-and-hepatic-issues-nonalcoholic-fatty-liver-disease",
  "itunes:image": "",
  "description": "<p>How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> <strong>Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-5007?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> <strong>Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis</strong></a></li> </ul>",
  "content:encoded": "<p>How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?</p> <p>Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> Learn more about our memberships here</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-5007?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095\"> Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis</a></li> </ul>",
  "enclosure": "",
  "itunes:duration": "12:26",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics? Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.",
  "itunes:episodeType": "full"
}